Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Open-label, Four-period, Fixed-sequence Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on the Pharmacokinetics of Flurbiprofen, Omeprazole, Midazolam, and Their Respective Metabolites in Healthy Subjects

Next Previous
Trial Profile

A Single-center, Open-label, Four-period, Fixed-sequence Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on the Pharmacokinetics of Flurbiprofen, Omeprazole, Midazolam, and Their Respective Metabolites in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivasorexant (Primary) ; Flurbiprofen; Midazolam; Omeprazole
  • Indications Binge-eating disorder
  • Focus Pharmacokinetics
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 24 Mar 2023 Results assessing the effect of Act-539313 on the pharmacokinetics of flurbiprofen, omeprazole and midazolam in healthy adults, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 03 May 2022 Status changed from recruiting to completed.
  • 25 Feb 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top